Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04711746

Is Clonal Hematopoiesis of Indeterminate Potential Associated With Unprovoked Pulmonary Embolism?

The clonal hematopoiesis of indetermined prognosis (CHIP) has been described as risk factor for juvenile atherosclerosis. Moreover, some of CHIP genes are responsible of myeloproliferative disorders. Venous thrombosis are frequent in these disorders. The purpose of this project is to determine if CHIP is frequent in unprovoked pulmonary embolism and could be part of the pathophysiology.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Pulmonary Embolism Cardiovascular Diseases Embolism Embolism and Thrombosis Hematopoiesis Lung Diseases Respiratory Tract Diseases Vascular Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • For cases : Previous proximal unprovoked pulmonary embolism, negative thrombophilia screening.
  • For control : Previous proximal provoked pulmonary embolism, negative thrombophilia screening.

Exclusion criteria

  • Age superior to 65 years old,
  • Active cancer

Treatment and study plan

Blood sample

Biological

Blood sample withdrawal in order to perform DNA sequencing

Primary outcomes

  1. Variation of CHIP markers between patients groups

    Time frame: up to 2 years

    Variation of CHIP markers (clonal hematopoiesis of indetermined prognosis ) between patients groups.

    CHIP concept have been defined as a mutation of preleukemic genes at an allelic variation inferior to 2% associated with normal complete blood count.

Study contacts

Contact information is provided by the study sponsor or research team.

Simon SOUDET, MD

CONTACT

[email protected]

03 22 88 72 89

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire, Amiens

Other

Registry information

Acronym: HEMEP

Important dates

Study start
2021
Primary completion
2026
Study completion
2026
First posted
Jan 15, 2021
Registry last updated
May 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.